Deregulation of Stat5 expression and activation causes mammary tumors in transgenic mice

International Journal of Cancer

Volumn 112, Issue 4, 2004, Pages 607-619

  Iavnilovitch, Elena ^a   Cardiff, Robert D ^b   Groner, Bernd ^c   Barash, Itamar ^a  

^a VOLCANI CENTER   (Israel)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

Cancer; Mammary gland; Oncogene; Stat5; Transgenic mice

Indexed keywords

BETA LACTOGLOBULIN; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; INITIATION FACTOR 4E; STAT5 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST TUMOR; CANCER INCIDENCE; CANCER MODEL; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; GENE ACTIVITY; GENE OVEREXPRESSION; LATENT PERIOD; MAMMARY GLAND; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN VARIANT; REGULATORY MECHANISM; REGULATORY SEQUENCE; TRANSACTIVATION; TRANSGENE; TRANSGENIC MOUSE; TUMOR DIFFERENTIATION; WILD TYPE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; MILK PROTEINS; PHENOTYPE; STAT5 TRANSCRIPTION FACTOR; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS;

EID: 7044272580     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20484     Document Type: Article

References (54)

1. Cardiff RD, Wellings SR. The comparative pathology of human and mouse mammary glands. J Mamm Gland Biol Neoplasia 1999;4:105-22.
2. Smalley M, Ashworth A. Stem cells and breast cancer: a field in transit. Nat Rev Cancer 2003;3:832-44.
3. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-51.
4. Blackwood MA, Weber BL. Recent advances in breast cancer biology. Curr Opin Oncol 1996;8:449-54.
5. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000;19:968-88.
6. Levy DE, Gilliland DG. Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene 2000;19:2505-10.
7. Mueller CW, Soler-Lopez M, Gewnner C, Groner B. X-ray crystal structure of Stat proteins and structure activity relationships. In: Hirano T, ed. Signal transducers and activators of transcription (STAT's): activation and biology. Kluwer Academic Publishers. 2003. pp. 311-25.
8. Li M, Liu X, Robinson G, Bar-Peled U, Wagner KU, Young WS, Hennighausen L, Furths PA. Mammary-derived signals activate programmed cell death during the first stage of mammary gland involution. Proc Natl Acad Sci USA 1997;94:3425-30.
9. Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K, Akira S, Clarke AR, Watson CJ. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 1999;13:2604-16.
10. Iavnilovitch E, Groner B, Barash I. Overexpression and forced activation of stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Mol Cancer Res 2002;1:32-47.
11. Watson CJ, Miller WR. Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer 1995;71:840-4.
12. Sartor CI, Dziubinski ML, Yu CL, Jove R, Ethier SP. Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. Cancer Res 1997;57:978-87.
13. Garcia R, Yu CL, Hudnall A, Catlett R, Nelson KL, Smithgall T, Fujita DJ, Ethier SP, Jove R. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 1997;8:1267-76.
14. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitski A, Kraker A Jove R. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001;20:2499-513.
15. Miyoshi K, Cui Y, Riedlinger G, Robinson P, Lehoczky J, Zon L, Oka T, Dewar K, Hennighausen L. Structure of the mouse Stat 3/5 locus: evolution from Drosophila to zebrafish to mouse. Genomics 2001;71:150-5.
16. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 1997;11:179-86.
17. Humphreys RC, Hennighausen L. Signal transducer and activator of transcription 5a influences mammary epithelial cell survival and tumorigenesis. Cell Growth Differ 1999;10:685-94.
18. Schmitt-Ney M, Doppler W, Ball RK, Groner B. Beta-casein gene promoter activity is regulated by the hormone-mediated relief of transcriptional repression and a mammary-gland-specific nuclear factor. Mol Cell Biol 1991;11:3745-55.
19. Pierre S, Jolivet G, Devinoy E, Theron MC, Malienou-N'Gassa R, Puissant C, Houdebine LM. A distal region enhances the prolactin induced promoter activity of the rabbit alpha sl-casein gene. Mol Cell Endocrinol 1992;87:147-56.
20. Burdon TG, Maitland KA, Clark AJ, Wallace R, Watson CJ. Regulation of the sheep beta-lactoglobulin gene by lactogenic hormones is mediated by a transcription factor that binds an interferon-gamma activation site-related element. Mol Endocrinol 1994;8:1528-36.
21. Liu X, Robinson GW, Gouilleux F, Groner B, Hennighausen L. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci USA 1995;92:8831-5.
22. Moriggl R, Gouilleux-Gruart V, Jahne R, Berchtold S, Gartmann C, Liu X, Hennighausen L, Sotiropoulos A, Groner B, Gouilleux F. Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype. Mol Cell Biol 1996;16:5691-700.
23. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945-54.
24. Ren S, Cai HR, Li M, Furth PA. Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene 2002;21:4335-9.
25. Gouilleux F, Wakao H, Mundt M, Groner B. Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J 1994;13:4361-9.
26. Berchtold S, Moriggl R, Gouilleux F, Silvennoinen O, Beisenherz C, Pfitzner E, Wissler M, Stocklin E, Groner B. Cytokine receptor-independent, constitutively active variants of STAT5. J Biol Chem 1997;272:30237-43.
27. Danielson KG, Oborn CJ, Durban EM, Butel JS, Medina D. Epithelial mouse mammary cell line exhibiting normal morphogenesis in vivo and functional differentiation in vitro. Proc Natl Acad Sci USA 1984;81:3756-60.
28. German T, Barash I. Characterization of an epithelial cell line from bovine mammary gland. In Vitro Cell Dev Biol Anim 2002;38:282-92.
29. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000;19:2468-73.
30. Reichenstein M, Gottlieb H, Damari GM, Iavnilovitch E, Barash I. A new beta-lactoglobulin-based vector targets luciferase cDNA expression to the mammary gland of transgenic mice. Transgenic Res 2001;10:445-56.
31. Mahler JF, Stokes W, Mann PC, Takaoka M, Maronpot RR. Spontaneous lesions in aging FVB/N mice. Toxicol Pathol 1996;24:710-6.
32. Landesman-Bollag E, Romieu-Mourez R, Song DH, Sonenshein GE, Cardiff RD, Seldin DC. Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 2001;20:3247-57.
33. Rosen P. Rosen's breast pathology, 2nd ed. Philadelphia: Lippincott Williams and Wilkins, 2001.
34. Tavassoli FA. Pathology of the breast, 2nd ed. New York: McGraw-Hill, 1999.
35. Saji S, Jensen EV, Nilsson S, Rylander T, Warner M, Gustafsson JA. Estrogen receptors alpha and beta in the rodent mammary gland. Proc Natl Acad Sci USA 2000;97:337-42.
36. Su L, Morgan PR, Lane EB. Expression of cytokeratin messenger RNA versus protein in the normal mammary gland and in breast cancer. Hum Pathol 1996;27:800-6.
37. Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D, Smith M. MUC1 and the immunobiology of cancer. J Mamm Gland Biol Neoplasia 2002;7:209-21.
38. Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Breast Cancer Res Treat 1998;52:1-15.
39. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994;369:669-71.
40. Li BD, Gruner JS, Abreo F, Johnson LW, Yu H, Nawas S, McDonald JC, DeBenedetti A. Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann Surg 2002;235:732-8.
41. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-88.
42. Chiarle R, Pagano M, Inghirami G. The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res 2001;3:91-4.
43. Poola I. Molecular assay to generate expression profile of eight estrogen receptor alpha isoform mRNA copy numbers in picogram amounts of total RNA from breast cancer tissues. Anal Biochem 2003;314:217-26.
44. Rosner A, Miyoshi K, Landesman-Bollag E, Xu X, Seldin DC, Moser AR, MacLeod CL, Shyamala G, Gillgrass AE, Cardiff RD. Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol 2002;161:1087-97.
45. Maurer AB, Wichmann C, Gross A, Kunkel H, Heinzel T, Ruthardt M, Groner B, Grez M. The Stat5-RARalpha fusion protein represses transcription and differentiation through interaction with a corepressor complex. Blood 2002;99:2647-52.
46. Nakajima H, Brindle PK, Handa M, Ihle JN. Functional interaction of STAT5 and nuclear receptor co-repressor SMRT: implications in negative regulation of STAT5-dependent transcription. EMBO J 2001;20:6836-44.
47. Bao J, Zervos AS. Isolation and characterization of Nmi, a novel partner of Myc proteins. Oncogene 1996;12:2171-6.
48. Zhu M, John S, Berg M, Leonard WJ. Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling. Cell 1999;96:121-30.
49. De Benedetti A, Harris AL. eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol 1999;31:59-72.
50. Matsumura I, Kitamura T, Wakao H, Tanaka H, Hashimoto K, Albanese C, Downward J, Pestell RG, Kanakura Y. Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J 1999;18:1367-77.
51. Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C, Doppler W. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res 2002;8:3065-74.
52. Yu H, Jove R. The STATs of cancer: new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
53. Felsher DW. Cancer revoked: oncogenes as therapeutic targets. Nat Rev Cancer 2003;3:375-80.
54. Barash I, Faerman A, Puzis R, Peterson D, Shani M. Synthesis and secretion of caseins by the mouse mammary gland: production and characterization of new polyclonal antibodies. Mol Cell Biochem 1995;144:175-80.